SAN FRANCISCO – Novartis has formed an in-house molecular diagnostics unit in order to improve the co-development of companion diagnostics and drugs, a company official told GenomeWeb Daily News today.

The group, co-located in Cambridge, Mass., and Basel, Switzerland, was created in January and should have around 50 to 60 staffers by the end of the year, said Michael Nohaile, head of Novartis Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.